TY - JOUR
T1 - Biosimilars for Retinal Diseases
T2 - An Update
AU - Sharma, Ashish
AU - Kumar, Nilesh
AU - Parachuri, Nikulaa
AU - Bandello, Francesco
AU - Kuppermann, Baruch D.
AU - Loewenstein, Anat
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Purpose: To review the biosimilars of anti–vascular endothelial growth factor agents for retinal diseases and provide an update about their development. Design: Literature review. Methods: A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. Results: To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. Conclusion: Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions.
AB - Purpose: To review the biosimilars of anti–vascular endothelial growth factor agents for retinal diseases and provide an update about their development. Design: Literature review. Methods: A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. Results: To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. Conclusion: Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions.
UR - http://www.scopus.com/inward/record.url?scp=85099701073&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2020.11.017
DO - 10.1016/j.ajo.2020.11.017
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 33309691
AN - SCOPUS:85099701073
SN - 0002-9394
VL - 224
SP - 36
EP - 42
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -
